Alpha Cognition’s (ACOG) “Buy” Rating Reiterated at HC Wainwright

Alpha Cognition (NASDAQ:ACOG)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $20.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 261.66% from the company’s current price.

Separately, Raymond James raised shares of Alpha Cognition to a “moderate buy” rating in a research note on Tuesday, March 25th.

Alpha Cognition Stock Performance

Shares of ACOG opened at $5.53 on Monday. The company has a market capitalization of $88.59 million, a PE ratio of -2.16 and a beta of 2.50. The stock’s 50-day moving average is $5.85. Alpha Cognition has a 1 year low of $4.66 and a 1 year high of $7.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. National Bank of Canada FI bought a new position in shares of Alpha Cognition during the 4th quarter valued at about $69,000. Manatuck Hill Partners LLC bought a new stake in Alpha Cognition during the 4th quarter worth approximately $395,000. Tudor Investment Corp ET AL acquired a new stake in Alpha Cognition during the 4th quarter worth approximately $412,000. MYDA Advisors LLC bought a new position in Alpha Cognition in the fourth quarter valued at approximately $589,000. Finally, Bleichroeder LP acquired a new position in shares of Alpha Cognition in the fourth quarter valued at approximately $1,024,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.